Bilaketaren emaitzak - Christine A. Pratilas

Findu emaitzak
  1. 1
    Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

    Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response nork Christine A. Pratilas, David B. Solit

    Argitaratua 2010
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Targeting Oncogenic BRAF in Human Cancer

    Targeting Oncogenic BRAF in Human Cancer nork Christine A. Pratilas, Feng Xing, David B. Solit

    Argitaratua 2010
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor

    From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor nork Kathryn M. Lemberg, Jiawan Wang, Christine A. Pratilas

    Argitaratua 2020
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  4. 4
    BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors

    BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors nork Karisa C. Schreck, Stuart A. Grossman, Christine A. Pratilas

    Argitaratua 2019
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  5. 5
    <sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

    <sup>V600E</sup> BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway nork Christine A. Pratilas, Barry S. Taylor, Qing Ye, Agnès Viale, Chris Sander, David B. Solit, Neal Rosen

    Argitaratua 2009
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

    Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance nork Grazia Ambrosini, Christine A. Pratilas, Li-Xuan Qin, Madhavi Tadi, Oliver Surriga, Richard D. Carvajal, Gary K. Schwartz

    Argitaratua 2012
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Models from experiments: combinatorial drug perturbations of cancer cells

    Models from experiments: combinatorial drug perturbations of cancer cells nork Sven Nelander, Weiqing Wang, Bengt‐Olof Nilsson, Qing‐Bai She, Christine A. Pratilas, Neal Rosen, Peter Gennemark, Chris Sander

    Argitaratua 2008
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors

    Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors nork Jiawan Wang, Kai Pollard, Amy N. Allen, Tushar Tomar, Dirk Pijnenburg, Zhan Yao, Fausto J. Rodríguez, Christine A. Pratilas

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Integrated molecular and clinical analysis of BRAF-mutant glioma in adults

    Integrated molecular and clinical analysis of BRAF-mutant glioma in adults nork Karisa C. Schreck, Pinky Langat, Varun Bhave, Taibo Li, E. L. Woodward, Christine A. Pratilas, Charles G. Eberhart, Wenya Linda Bi

    Argitaratua 2023
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat

    Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat nork Erin E. Resch, Stavriani C. Makri, Paola Ghanem, Ezra Baraban, Kenneth J. Cohen, Alan R. Cohen, Evan J. Lipson, Christine A. Pratilas

    Argitaratua 2025
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines

    BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines nork Rébecca Leboeuf, Jacqueline E. Baumgartner, Miriam Benezra, Roberta Malaguarnera, David B. Solit, Christine A. Pratilas, Neal Rosen, Jeffrey A. Knauf, James A. Fagin

    Argitaratua 2008
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition

    3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition nork David B. Solit, Elmer Santos, Christine A. Pratilas, Jose Lobo, Maxim A. Moroz, Shangde Cai, Ronald Blasberg, Judith S. Sebolt‐Leopold, Steven M. Larson, Neal Rosen

    Argitaratua 2007
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer

    Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer nork Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal Rosen, Nathanael S. Gray, Kwok‐Kin Wong, Pasi A. Jänne

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies

    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies nork J. Kyle Bruner, S. Hayley, Li Li, Alice Can Ran Qin, Michelle A. Rudek, Richard J. Jones, Mark J. Levis, Keith W. Pratz, Christine A. Pratilas, Donald Small

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Novel PAX3::MAML3 fusion identified in alveolar rhabdomyosarcoma, using DNA methylation profiling to expand the genetic spectrum of “fusion-positive” cases

    Novel PAX3::MAML3 fusion identified in alveolar rhabdomyosarcoma, using DNA methylation profiling to expand the genetic spectrum of “fusion-positive” cases nork Josephine K. Dermawan, Faizan Malik, John Gross, Ezra Baraban, Christine A. Pratilas, Wadad Mneimneh, Matteo Trucco, Wenyue Sun, Frederic G. Barr, Felipe D’Almeida Costa, Karen Fritchie

    Argitaratua 2024
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells

    Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells nork Anil Korkut, Weiqing Wang, Emek Demir, Bülent Arman Aksoy, Xiaohong Jing, Evan Molinelli, Özgün Babur, Debra L. Bemis, S. Onur Sumer, David B. Solit, Christine A. Pratilas, Chris Sander

    Argitaratua 2015
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Size-based detection of sarcoma circulating tumor cells and cell clusters

    Size-based detection of sarcoma circulating tumor cells and cell clusters nork Masanori Hayashi, Peixuan Zhu, Gregory McCarty, Christian F. Meyer, Christine A. Pratilas, Adam S. Levin, Carol D. Morris, Catherine M. Albert, Kyle W. Jackson, Cha-Mei Tang, David M. Loeb

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations

    Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations nork Doreen N. Palsgrove, Yunjie Li, Christine A. Pratilas, Ming‐Tseh Lin, Aparna Pallavajjalla, Christopher D. Gocke, Angelo M. De Marzo, Andrés Matoso, George J. Netto, Jonathan I. Epstein, Pedram Argani

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    BRAF mutation predicts sensitivity to MEK inhibition

    BRAF mutation predicts sensitivity to MEK inhibition nork David B. Solit, Levi A. Garraway, Christine A. Pratilas, Ayana Sawai, Gad Getz, Andrea Basso, Qing Ye, Jose Lobo, Yuhong She, Iman Osman, Todd R. Golub, Judith S. Sebolt‐Leopold, William R. Sellers, Neal Rosen

    Argitaratua 2005
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

    The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner nork Eric W. Joseph, Christine A. Pratilas, Poulikos I. Poulikakos, Madhavi Tadi, Weiqing Wang, Barry S. Taylor, Ensar Halilovic, Yogindra Persaud, Feng Xing, Agnès Viale, James Tsai, Paul B. Chapman, Gideon Bollag, David B. Solit, Neal Rosen

    Argitaratua 2010
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: